Patients with hypertension now have a cheaper medication option following the US Food & Drug Administration's approval of generic olmesartan medoxomil and hydrochlorothiazide tablets.
Aurobindo Pharma USA's latest addition to pharmacies across the country was previously only available as branded Benicar HCT, produced by Daiichi Sankyo. The drug is classed as an angiotensin II receptor blocker / ARBS and diuretic combination. A generic version of Benicar (olmesartan medoxomil) is already available, but Aurobindo's latest addition to the market is the first generic combining olmesartan medoxomil and hydochorothiazide to gain approval for hypertension treatment in the US.
The new generic prescription medication is available in three doses: 20 mg/12.5 mg, 40 mg/12.5 mg, and 40 mg/25 mg and is indicated for treatment of hypertension. The recommended starting dose for the medication is 40mg/12.5mg once daily in patients whose high blood pressure is not controlled by olmesartan monotherapy.
Three contraindications are listed in the medication's prescription information:
- Patients with hypersensitivity to any component of olmesartan medoxomil and hydrochlorothiazide tablets.
- Patients with anuria.
- For coadministration with aliskiren in patients with diabetes.
May is America Stroke Month and National High Blood Pressure Education Month. As part of the awareness campaign, the American Heart Association is calling on people to check their blood pressure by May 17th - World Hypertension Day. It warns about three in four people who have a first stroke have a blood pressure greater than 140/90 mm Hg.
Hypertension affects around one-third of American adults, according to figures from the Centers for Disease Control and Prevention (CDC). It increases the risk of heart disease and stroke, which are two of the nation's leading causes of death. Despite this, CDC data suggests only half of those with high blood pressure have their condition under control.